Patrizia Farci
#135,705
Most Influential Person Now
Italian scientist and hepatologist
Patrizia Farci's AcademicInfluence.com Rankings
Patrizia Farciphilosophy Degrees
Philosophy
#10375
World Rank
#14212
Historical Rank
Logic
#7256
World Rank
#8959
Historical Rank
Download Badge
Philosophy
Patrizia Farci's Degrees
- Bachelors Biology University of Milan
- PhD Hepatology University of Florence
Similar Degrees You Can Earn
Why Is Patrizia Farci Influential?
(Suggest an Edit or Addition)According to Wikipedia, Patrizia Farci is an Italian scientist and hepatologist. She is chief of the hepatic pathogenesis section at the National Institute of Allergy and Infectious Diseases. Farci conducts translational research in the field of liver diseases, particularly in the study of pathogenesis of acute and chronic viral hepatitis. She was previously a full professor of medicine and director of the liver unit and the postgraduate school of gastroenterology at the University of Cagliari.
Patrizia Farci's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. (2004) (1118)
- The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. (2000) (943)
- Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. (1996) (626)
- A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. (1991) (572)
- Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. (1994) (515)
- Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome [Science 1989;244:359-362]. (2002) (461)
- Lack of protective immunity against reinfection with hepatitis C virus. (1993) (435)
- Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B (2009) (430)
- INFLUENCE OF DELTA INFECTION ON SEVERITY OF HEPATITIS B (1982) (405)
- Lack of protective immunity against reinfection with hepatitis C virus (1992) (393)
- Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. (1983) (357)
- Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. (2009) (317)
- SEROLOGICAL RESPONSE TO THE HEPATITIS DELTA VIRUS IN HEPATITIS D (1987) (304)
- Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children (1994) (286)
- Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1 (1995) (281)
- Treatment of chronic hepatitis D with interferon alfa-2a. (1994) (281)
- Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B (2006) (280)
- Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. (2004) (251)
- Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. (2004) (249)
- Delta hepatitis: an update. (2003) (227)
- Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome (2002) (225)
- Clinical significance of hepatitis C virus genotypes and quasispecies. (2000) (216)
- A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. (1996) (207)
- Hepatitis C virus-associated fulminant hepatic failure. (1996) (175)
- A randomized controlled trial of lymphoblastoid interferon‐α in patients with chronic hepatitis B lacking HBeAg (1992) (163)
- Clinical Features of Hepatitis D (2012) (141)
- Microsomal autoantibodies in chronic infection with the HBsAg associated delta (delta) agent. (1983) (137)
- Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma (2012) (130)
- Epidemiologic patterns of infection with the hepatitis B virus-associated delta agent in Italy. (1983) (118)
- Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B (2012) (118)
- B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus–associated acute liver failure (2010) (105)
- Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway. (2018) (99)
- New insights into the HCV quasispecies and compartmentalization. (2011) (95)
- Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy (2007) (92)
- Hepatitis B virus DNA in the serum of Sardinian blood donors negative for the hepatitis B surface antigen. (1989) (90)
- The natural history of infection with hepatitis C virus (HCV) in chimpanzees: comparison of serologic responses measured with first- and second-generation assays and relationship to HCV viremia. (1992) (89)
- Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. (2013) (89)
- Chronic Hepatitis in Carriers of Hepatitis B Surface Antigen, with Intrahepatic Expression of the Delta Antigen (1983) (87)
- Diagnostic and prognostic significance of the IgM antibody to the hepatitis delta virus. (1986) (84)
- Circulating let‐7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C (2016) (83)
- Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. (2006) (78)
- Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. (1987) (76)
- Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating acute hepatitis B progressive to chronicity. (1983) (76)
- Identification of microRNAs specifically expressed in hepatitis C virus‐associated hepatocellular carcinoma (2013) (72)
- Hepatitis D virus and human immunodeficiency virus antibodies in parenteral drug abusers who are hepatitis B surface antigen positive. (1988) (71)
- CLINICAL SIGNIFICANCE OF ANTIBODY TO THE HEPATITIS DELTA VIRUS IN SYMPTOMLESS HBsAg CARRIERS (1985) (67)
- Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha‐2a (2008) (67)
- Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. (1999) (66)
- Evaluation of antibodies to hepatitis C virus in a long-term prospective study of posttransfusion hepatitis among thalassemic children: comparison between first- and second-generation assay. (1993) (65)
- Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. (2010) (63)
- Independent expression of serological markers of thyroid autoimmunity and hepatitis virus C infection in the general population: Results of a community-based study in northwestern Sardinia (1999) (62)
- Liver Regeneration Signature in Hepatitis B Virus (HBV)-Associated Acute Liver Failure Identified by Gene Expression Profiling (2012) (59)
- Analysis of long noncoding RNA expression in hepatocellular carcinoma of different viral etiology (2016) (57)
- Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure (2018) (55)
- Treatment of chronic hepatitis D (2007) (55)
- The quasispecies of hepatitis C virus and the host immune response (2004) (55)
- Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. (2010) (52)
- In Vivo Study of the HC-TN Strain of Hepatitis C Virus Recovered from a Patient with Fulminant Hepatitis: RNA Transcripts of a Molecular Clone (pHC-TN) Are Infectious in Chimpanzees but Not in Huh7.5 Cells (2007) (51)
- Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. (2006) (51)
- Diminished viral replication and compartmentalization of hepatitis C virus in hepatocellular carcinoma tissue (2016) (49)
- Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus - associated hepatocellular carcinoma (2014) (49)
- The role of pre-core hepatitis B virus mutants on the long-term outcome of chronic hepatitis B virus hepatitis. A longitudinal study. (1994) (47)
- Association of chronic hepatitis C with recurrent brief depression. (2012) (46)
- Treatment of chronic hepatitis D: New advances, old challenges (2006) (45)
- Acute viral hepatitis in Saudi Arabia: seroepidemiological analysis, risk factors, clinical manifestations, and evidence for a sixth hepatitis agent. (1995) (42)
- 103 VIROLOGICAL AND BIOCHEMICAL RESPONSE IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON ALFA-2A (40KD) WITH OR WITHOUT LAMIVUDINE: RESULTS OF 4-YEAR FOLLOW-UP (2008) (40)
- Infection with the delta agent in children. (1985) (40)
- Natural history of hepatitis C in thalassemia major: a long‐term prospective study (2013) (40)
- Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, Challenge (2015) (39)
- Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis (2012) (39)
- Integrated ordination of miRNA and mRNA expression profiles (2015) (38)
- Molecular Signature and Mechanisms of Hepatitis D Virus–Associated Hepatocellular Carcinoma (2018) (38)
- Experimental transmission of hepatitis C virus-associated fulminant hepatitis to a chimpanzee. (1999) (37)
- 106 International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2A (40KD) (PEGASYS®) and ribavirin (copegus®) (2003) (37)
- Exceptional Heterogeneity in Viral Evolutionary Dynamics Characterises Chronic Hepatitis C Virus Infection (2016) (35)
- Systematic transcriptome analysis reveals elevated expression of alcohol‐metabolizing genes in NAFLD livers (2016) (33)
- 924 INCREASING RATES OF HBsAg CLEARANCE AND SEROCONVERSION IN PATIENTS WITH HBeAg-NEGATIVE DISEASE TREATED WITH PEGINTERFERON ALFA-2A ± LAMIVUDINE: RESULTS OF 5-YEAR POST-TREATMENT FOLLOW UP (2009) (32)
- Hepatitis delta virus infection in Kenya. Its geographic and tribal distribution. (1986) (32)
- Inhibition of hepatitis delta virus (HDV) replication by lymphoblastoid human alpha interferon. (1987) (28)
- Studies of HBV replication during acute hepatitis followed by recovery and acute hepatitis progressing to chronic disease. (1985) (26)
- Sequence analysis of hepatitis B virus genome of a new mutant of ayw subtype isolated in Sardinia. (1991) (25)
- Current and Future Management of Chronic Hepatitis D. (2018) (25)
- IgM antibody against hepatitis B core antigen (IgM anti-HBc): diagnostic and prognostic significance in acute HBsAg positive hepatitis. (1983) (25)
- Hepatitis C virus. The importance of viral heterogeneity. (2001) (24)
- [53] VIROLOGICAL AND BIOCHEMICAL RESPONSE IN PATIENTS WITH HBeAg-NEGATIVE CHB TREATED WITH PEGINTERFERON a-2a (40 kD) ± LAMIVUDINE: 3-YEAR FOLLOW-UP RESULTS (2007) (23)
- Prospective study of epidemic delta infection in drug addicts. (1983) (22)
- Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin. (2006) (22)
- Specificity of an anti-capsid antibody associated with Hepatitis B Virus-related acute liver failure. (2013) (21)
- Hepatitis type C after orthotopic liver transplantation: reinfection and disease recurrence. (1994) (21)
- The use of molecular assays in the management of viral hepatitis. (2008) (21)
- The economics of treating chronic hepatitis C patients with peginterferon α‐2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase * (2006) (20)
- HCV-associated lymphomas. (2003) (20)
- Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma (2018) (20)
- Microsomal autoantibodies in chronic infections with HBsAg associated delta agent (1983) (20)
- Markers of hepatitis C virus infection in sardinian blood donors: Relationship with alanine aminotransferase levels (1993) (19)
- Loss of the transforming growth factor‐β effector β2‐Spectrin promotes genomic instability (2017) (19)
- The role of delta superinfection in acute exacerbations of chronic type B hepatitis. (2008) (18)
- Endemic HBV infection, tissue autoantibodies and HLA. Analysis of a Sardinian population. (2008) (18)
- 98 EXTENDED (2 YEARS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IMPROVES SUSTAINED RESPONSE RATES IN GENOTYPE D PATIENTS WITH HBEAG NEGATIVE CHRONIC HEPATITIS B (2010) (18)
- A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook (2022) (17)
- An outbreak of delta agent among a group of drug addicts and their close contacts. (1984) (17)
- Treatment of chronic hepatitis delta virus (HDV) infection with human lymphoblastoid alpha interferon. (1989) (17)
- The aetiology of acute hepatitis in Zimbabwe. (1984) (16)
- Endpoints and New Options for Treatment of Chronic Hepatitis D (2021) (16)
- Hepatitis D (Delta) Virus (2007) (16)
- Interactions between hepatotropic viruses in patients with haemophilia. (1985) (16)
- 95 Peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudine (2004) (14)
- Hepatitis D Virus and Hepatocellular Carcinoma (2021) (14)
- Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis (2021) (11)
- Radioimmunoassay detection of IgM antibodies to the hepatitis B core antigen in HBsAg liver disease. (1982) (11)
- Loss of the TGF-β Effector β2SP Promotes Genomic Instability. (2016) (9)
- Delta hepatitis in Lebanon. Prevalence studies and a report on six siblings with chronic delta-positive active hepatitis. (1987) (9)
- Liver transplant for viral hepatitis. Recurrence of reinfection. (1991) (9)
- CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a (2009) (9)
- Immunity elicited by hepatitis C virus. (1995) (9)
- Distinctive HLA-II association with primary biliary cholangitis on the Island of Sardinia (2017) (9)
- Distinct Cytokine Profiles Correlate with Disease Severity and Outcome in Longitudinal Studies of Acute Hepatitis B Virus and Hepatitis D Virus Infection in Chimpanzees (2020) (9)
- 743 The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®] sustain responses 2 years post-treatment (2006) (9)
- IgM anti-HD in acute hepatitis D: diagnostic and prognostic significance. (1987) (8)
- Natural History and Experimental Models (2007) (8)
- Neutralizing antibodies to hepatitis C virus in perinatally infected children followed up prospectively. (2011) (8)
- Hepatitis delta virus (HDV) infection and disease. (1986) (7)
- Influence of alfa interferon on the natural history of chronic hepatitis D:dissociation of histologic and virologic response (2000) (7)
- Thrombin activity and oral anticoagulant therapy: a preliminary study. (1989) (6)
- Introduction of human immunodeficiency virus infection among parenteral drug abusers in Sardinia: a seroepidemiologic study. (1988) (6)
- Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HCC): Differences and Similarities with HBV-HCC (2021) (6)
- Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful? (2006) (6)
- 683 ON-TREATMENT HBSAG DECLINE IN HBEAG-NEGATIVE PATIENTS AS A PREDICTOR OF RESPONSE TO PEGINTERFERON ALFA-2A (40KD) THERAPY 3 YEARS POST-TREATMENT: POTENTIAL FOR RESPONSE-GUIDED THERAPY (2008) (6)
- Prevention of HCV infection in chimpanzees following antibody-mediated in vitro neutralization (1993) (6)
- Epidemiology of HDV infection in Sardinia, an island with a high endemicity for HBV. A multicentre study. (1991) (6)
- 1181 A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2A (40KD) (PEGSYS®) alone or in combination with lamivudine vs lamivudine in 546 patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B (2003) (6)
- 503 Early prediction of sustained virological response (SVR) during treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with chronic hepatitis C (CHC) and persistently normal alanine aminotransferase (ALT) levels (2004) (6)
- CLINICAL–LIVER, PANCREAS, AND BILIARY TRACT Long-Term Benefit of Interferon ! Therapy of Chronic Hepatitis D: Regression of Advanced Hepatic Fibrosis (2016) (5)
- Hepatitis B virus replication and clinical outcome in carriers of HBsAg. Perspectives of treatment with DNA inhibitors. (2008) (5)
- 730 PEGBELIVER STUDY: HBSAG DECLINE AT WEEK 24 OF EXTENDED PEGINTERFERON ALFA-2A (PEG-IFNα-2A) THERAPY IS SIGNIFICANTLY ASSOCIATED WITH POST-TREATMENT RESPONSE IN HBEAG-NEGATIVE GENOTYPE D PATIENTS (2011) (5)
- Animal Models of Hepatitis C Virus Infection (2013) (5)
- T lymphocyte subsets and viral infections in sardinian parenteral drug abusers: Relationship to HIV infection (1989) (5)
- Subclinical activation of fibrinolysis in atherosclerotic disease detected by Bβ 15–42 assay (1989) (4)
- Epidemiology and clinical course of delta infection in Britain. (1983) (4)
- Role of Hepatitis E Virus Infection in North American Patients With Severe Acute Liver Injury (2020) (4)
- Distinct disease features in chimpanzees infected with a precore HBV mutant associated with acute liver failure in humans (2020) (4)
- 524 RESPONSE-GUIDED PEGINTERFERON ALFA-2A THERAPY BASED ON HBSAG LEVELS AT WEEK 12 AND WEEK 24 OR 48 IMPROVES RESPONSE RATES IN HBEAG-NEGATIVE, GENOTYPE D PATIENTS (2012) (4)
- 421 A new bio-mathematical model to describe the dynamics of HBV-DNA and infected hepatocytes in HBEAG-negative/anti-HBE-positive chronic hepatitis B patients treated with peginterferon alfa-2A (40KD) (PEGASYS®), lamivudine, or PEGASYS® plus lamivudine combin (2004) (3)
- Randomized controlled trial of high and low doses of interferon (IFN) alpha-2a (Roferon-A) in chronic HDV hepatitis: an interim report (1991) (3)
- [Echocardiographic study at rest and during effort in adult asymptomatic thalassemic patients]. (1989) (3)
- Treatment of chronic delta hepatitis with higt and low doses of interferon alpha-2a. A randomizzed controlled trial (1990) (3)
- Anti-PF4 antibodies associated with disease severity in COVID-19 (2022) (3)
- Evidence for a relationship between high fibrinogen levels and decreased thrombin activity in vivo in elderly subjects. (1989) (3)
- Next‐generation sequencing of the intrahepatic antibody repertoire delineates a unique B‐cell response in HBV‐associated acute liver failure (2020) (3)
- Favourable response to lymphoblastoid interferon of anti-HBe and HBV-DNA positive chronic hepatitis B (1990) (2)
- The influence of human immunodeficiency virus (HIV) on the course of chronic delta hepatitis: A prospective study (1989) (2)
- Evolution of the viral quasispecies tracked by sequence analysis during interferon treatment of chronic hepatitis C. (1998) (2)
- Reflections on the History of HCV: A Posthumous Examination (2020) (2)
- PGI5 COST-EFFECTIVENESS OF TREATING ADULTS WITH CHRONIC HEPATITIS C (CHC) AND PERSISTENTLY NORMAL ALANINE AMINOTRANSFERASE (PNALT) WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS) (2004) (2)
- Anti-HBe and HBV-DNA positive chronic hepatitis B: Response to interferon therapy (1989) (2)
- Incidence of Hepatitis E Infection in American Patients With Suspected Drug-Induced Liver Injury Is Low and Declining: The DILIN Prospective Study (2022) (2)
- Delta infection in children. (1983) (2)
- Prevention and treatment of hepatitis delta virus infection. (1991) (1)
- A2 Molecular Evolution of Hepatitis C Virus (HCV) and Clinical Outcome in Patients With Hepatitis C (2012) (1)
- [Immunological aspects in anti-HIV seronegative drug addicts. Correlation with the duration of heroin addiction and other viral infections]. (1989) (1)
- A PCR analysis of reinfection and liver disease in liver transplant (OLT) due to hepatitis viruses (1991) (1)
- Su1800 Systematic Analysis of NAFLD Transcriptome Revealed Elevated Expression of Alcohol Metabolizing Genes in Mild and Severe NAFLD Livers (2015) (1)
- Sa1851 Prognostic Significance of TGF-β Signaling in Human Hepatocellular Carcinoma (2015) (1)
- Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants (2022) (1)
- [The presence of nucleotide sequences of the hepatitis B virus in the serum of HBsAg-negative blood donors in Sardinia]. (1990) (1)
- Transfusion-associated Hepatitis (TAH) in Polytransfused Thalassemic Children Following the Introduction of Anti-HCV Donor Screening in Sardinia (1994) (1)
- Natural history and experimental models of hepatitis C (2005) (1)
- [487] PREDICTORS OF HBsAg REDUCTION IN HBsAg- NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON a-2a (40 kD) ALONE OR IN COMBINATION WITH LAMIVUDINE (2007) (1)
- Tu1624 Dysregulated TGF-β Signaling Leads to Genomic Instability and Liver Cancer (2016) (0)
- [Platelet activation in vivo before and after hemodialysis using polyacrylonitrile filters]. (1988) (0)
- Prevalence of type-2 Diabetes in a populationof sardinian patients with chronic hepatitis C without cirrosis (2011) (0)
- Favourable response to lymphoblastoid interferon of anti-HBe positive chronic hepatitis type B (1990) (0)
- Hepatitis E prevalence and infection in solid‐organ transplant recipients in the United States (2022) (0)
- 682 HBVDNA SUPPRESSION INDUCED BY PEGINTERFERON ALFA-2A (40KD) BUT NOT BY LAMIVUDINE RESULTS IN HBSAG LOSS AND SEROCONVERSION AT 3 YEARS POST-TREATMENT (2008) (0)
- Immune Response to Hepatitis C Virus (2005) (0)
- Treatment of patients with Chronic Hepatitis Delta (2007) (0)
- 22 Co-infection par le virus de l’hépatite B et le virus de l’hépatite D (2020) (0)
- Painless thyroiditis a clinical report (1985) (0)
- P062: A randomized comparative open label trial of tenofovir monotherapy versus tenofovir plus telbuvidine dual therapy in spontaneous reactivation of hepatitis B (NCT01732224) (2015) (0)
- Virological mechanisms of viral persistence, resolution and reinfection (2002) (0)
- P1191 HETEROGENEOUS EVOLUTIONARY DYNAMICS OF CHRONIC HEPATITIS-C INFECTION PREDICT LONG-TERM PERSISTENCE OF VIRUS THROUGH TREATMENT (2014) (0)
- I-105 Advances in HCV-associated hepatocellular carcinoma (2018) (0)
- Transfusion-associated hepatitis (TAH) in prospectively followed thalassemic children on long-term transfusion therapy following anti-HCV donor screening. An interim report (2000) (0)
- Abstract 3900: Genomic landscape of human cancer reveals dysregulated TGF-β signaling with prognostic significance (2015) (0)
- Viral Escape Mechanisms in Hepatitis C and the Clinical Consequences of Persistent Infection (2020) (0)
- The response to lymphoblastoid interferon of anti-HBe and HBV-DNA positive patients with chronic hepatitis B (1990) (0)
- P063: Genome‐wide analysis of mRNA and miRNA expression of hepatitis B virus (HBV)‐associated acute liver failure reveals a dominant B‐cell disease signature (2015) (0)
- Viral load reduction and virological response in HBeAg-negative chronic epatiti B treated with Peginterferon alfa 2a (PEG-IFN alfa 2a) (2011) (0)
- Evolution of the HCV quasispecies in perinatally infected children with chronic hepatitis C. (2002) (0)
- Issue Information (2020) (0)
- HDV1 O‐04: Molecular characterization of hepatitis D virus associated hepatocellular carcinoma (2015) (0)
- Gene signature of HDV-associated hepatocellular carcinoma (HCC): differences with HCC associated with other hepatitis viruses (2018) (0)
- Prospective study of transfusion-associated hepatitis in thalassemic children following the introduction of anti-HCV donor screening. (2002) (0)
- [Epidemiologic and clinical study of HIV infection in Cagliari]. (1987) (0)
- 618 A Novel Somatic Mutation of β2sp Inactivates the TGF-β Pathway and Promotes Alcohol Induced HCC (2013) (0)
- Infection with thedelta agent inchildren (2011) (0)
- Issue Information (2020) (0)
- [The presence of nucleotide sequences of the hepatitis B virus in peripheral lymphocytes of patients with acute hepatitis B]. (1989) (0)
- Integrated ordination of miRNA and mRNA expression profiles (2015) (0)
- Sequence analysis of Hepatitis B Virus mutants isolated in Sardinia i HBsAg negative chronic hepatitis (1991) (0)
- [Primary hepatocarcinoma and hepatitis B virus in Sardinia]. (1988) (0)
- Title Predicting response to peginterferon α2 a , lamivudine and thetwo combined for HBeAg-negative chronic hepatitis B (2007) (0)
- P.241 Treatment outcomes in patients with hepatitis C virus genotype 1a and 1b and persistently ‘normal’ alanine aminotransferase (ALT) levels receiving peginterferon alpha-2a (40KD) plus ribavirin (2006) (0)
- HCV1 O‐03: Virus‐specific dimeric IgA: a new biomarker for acute viral hepatitis infections? (2015) (0)
- Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus - associated hepatocellular carcinoma (2014) (0)
- Diminished Replication and Viral Compartmentalization of Hepatitis C Virus in Hepatocellular Carcinoma Tissue (2016) (0)
- G105 Profibrogenic Chemokines and Viral Evolution Predict Rapid Progression of Hepatitis C to Cirrhosis (2013) (0)
- Molecular basis of viral resistance to interferon in chronic hepatitis C (2001) (0)
- Abstract 4425: Comprehensive study of TGF-β pathway-driven functional molecular characterization of human hepatocellular cancer (2016) (0)
- Molecular dynamics of HCV hypervariable region 1 (HCV HVR1) quasispecies in chronically HCV-infected chimpanzees (2002) (0)
- HCV diversity, dynamics and turnover (2001) (0)
- Rapidly progressive HBsAg hepatitis in Italy: a syndrome of Delta hepatitis virus superinfection (1986) (0)
- 1171 Molecular epidemiology of hepatitis B virus in patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B from different geographical areas. Data from the PEGASYs® study in HBE-antigen-negative CHB (2003) (0)
- Tu1626 Integrated TGF-B Pathway Driven Functional Molecular Portrait of Human Hepatocellular Cancer (2016) (0)
- Liver and biliary Infection with the delta agent in children (2006) (0)
- 19. Hepatitis D (2011) (0)
- Evolution of the HCV quasispecies and pattern of response to interferon therapy in patients with chronic hepatitis C (1999) (0)
- Abstract 3594: The TGF-β effector β2SP depletion abrogates DNA damage repair (2016) (0)
- Prevalence and clinical significance of serum HBV-DNA in the course of anti-HBe positive chronic hepatitis B in Sardinia (1988) (0)
- Abstract 1775: High resolution characterization of human hepatocellular cancer (HCC) reveals a novel inactivating mutation in the TGF-β pathway that promotes alcohol induced HCC. (2013) (0)
- [514] PREDICTION OF LIVER HISTOPATHOLOGY BY NON-INVASIVE MODELS IN HBeAg-POSITIVE AND HBeAg-NEGATIVE CHRONIC HEPATITIS B (2007) (0)
- [Physical, chemical and microbiological study of street heroin present on the Cagliari market]. (1982) (0)
- Individualized long-term treatment of chronic hepatitis C with interferon alpha (IFN alpha)-2a. (2001) (0)
- Treatment of anti-HBe and HBV-DNA positive chronic hepatitis with lymphoblastoid interferon alfa (1991) (0)
- The clinical significance of the delta antigen-antibody system in hepatitis B infections. (1982) (0)
- P.112 Response is sustained two years post-treatment in the majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®] (2006) (0)
- F-7 Insulin resistance does not affect sustained virologic response in patients with chronic hepatitis C without cirrhosis treated with peg-interferon alfa 2a and ribavirin (2011) (0)
- LONG-TERM EFFECT OF LYMPHOBLASTOID INTERFERON THERAPY OF ANTI- HBE AND HBV-DNA POSITIVE CHRONIC HEPATITIS (1990) (0)
- Chronic viral hepatitis D (2012) (0)
- Analysis of long noncoding RNA expression in hepatocellular carcinoma of different viral etiology (2016) (0)
- O.152 Treatment of chronic hepatitis D (2006) (0)
- The natural course of chronic HBsAg positive hepatitis with serum HBV-DNA and anti-HBe in Sardinia (1988) (0)
- F-51 Virological response and HBV-DNA reduction during therapy with peginterferon alpha-2a (PEG-IFNα-2a) in patients affected by HBeAg-negative chronic hepatitis B (2012) (0)
This paper list is powered by the following services:
Other Resources About Patrizia Farci
What Schools Are Affiliated With Patrizia Farci?
Patrizia Farci is affiliated with the following schools:
